MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
about
Identification of druggable cancer driver genes amplified across TCGA datasetsTargeting the hepatocyte growth factor-cMET axis in cancer therapyClinical significance of MET in gastric cancerMolecular Dimensions of Gastric Cancer: Translational and Clinical PerspectivesMET inhibitors in combination with other therapies in non-small cell lung cancerNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityTargeted therapies in development for non-small cell lung cancerPhase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerDurable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationEmerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Targeting MET Amplification as a New Oncogenic Driver.Activation of RAS family members confers resistance to ROS1 targeting drugs.High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutatedOutgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.Importance of molecular features of non-small cell lung cancer for choice of treatment.Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumorsSynthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapyRON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in MelanomaActivation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancerKnockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.Gastric cancer-molecular and clinical dimensions.Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.c-MET as a potential therapeutic target and biomarker in cancer.Multidimensional control of cell structural robustness.Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.
P2860
Q21090621-FFA240A1-B26E-484D-A7EE-DB1D78894C5FQ24606259-1CF44726-8A5B-4979-9F9F-A55CE2739537Q26776190-0688C47E-CE4B-4842-8661-153E17B63266Q26779725-3C099FC8-DB9E-4C65-A9C5-DEA50DFEA8BDQ26823203-AD7CC710-367C-47E1-B1D4-D07C855CC156Q26992272-08A219C3-5380-4D72-BBD1-8241F6459454Q27022852-8E33D4C6-1AF5-4535-A29B-A96AD40B19FBQ27320322-2C59EC71-69B5-4D50-AAFF-7DDC6EFB8199Q27851725-E51C0F53-1508-4981-AF7B-EDE6F0EADBABQ28480605-D9097F07-BB25-4167-87F6-3BEC73E41B37Q33769437-222C1670-72B5-4E6D-AA13-3A595FF3E150Q33917507-F16962D0-704B-4987-80CF-41971F2ECA70Q34309927-92F60A85-D848-4DB3-A9A4-B6126CFBED76Q34463388-C3F11F1F-083E-4C29-B155-D73FF4D35EEBQ34541232-DF845700-A2ED-47B7-817E-032B560E8E72Q34687503-B5C21E43-ADB5-4162-8AD7-14DC16D9DB61Q34838412-4F85DDB6-54BB-43B2-A1DD-73FCB1C9079BQ35053276-37AFB256-1339-4A4B-81D0-D1AD13BC3432Q35129076-2405BFD0-3E86-4330-BEF2-32B616C0C115Q35146597-1988B811-D7C8-486B-AF33-25A16D7FBD49Q35238436-B1283D0F-BDF0-4320-AD16-FEB3E9EBB8A8Q35612939-E5F0E37F-C6E8-4440-B681-AF92CC39193BQ35666332-EDC1B0C6-CD9A-44D0-8618-B639310B0053Q35956303-309776C4-5CEF-4301-B20D-EA47B04C95AFQ36383040-E374D54A-B455-4CED-ABF0-E6258412CC01Q36451726-64C6C768-DAE5-42E0-98A3-4F0C8E8AA216Q36561734-480F5D06-6D87-4166-BBAB-58D6C3E617F3Q36972377-E869F3D3-FE94-440E-B834-177B9C7CBE2FQ37051546-DD73311F-F2F9-422A-9132-59D216D5917BQ37104714-3094C87C-8C23-4F74-9A50-B1C39244413EQ37301868-C7E04D4E-209E-4CD3-9B65-D10CD32FEACCQ37536016-979BEA56-1542-4171-BEDC-4387B0D3ECBDQ37591176-E806DA30-8255-4492-8617-8DF35A21ABE2Q37628915-B3EBDCBF-12A9-4654-92EB-B30C33822922Q37666955-EF3D8488-6E9F-45F9-B5AD-86D4A7185885Q37724940-BC8D730A-D7ED-4D62-9658-A9AD5C773B7BQ37962905-871CF4E2-105A-42F5-9A96-93E0D3AF60B9Q38107864-9CC2E7A2-1AB7-425B-9648-1A13855F4467Q38188598-56A1E42D-72E0-43DA-942A-A973F17A1BFDQ38213830-4B6FEC1F-02B5-4EB0-93FD-7F6884E7F025
P2860
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@en
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@nl
type
label
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@en
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@nl
prefLabel
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@en
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@nl
P2093
P50
P1433
P1476
MET and KRAS gene amplificatio ...... ET tyrosine kinase inhibitors.
@en
P2093
Elena Ghiso
J Rafael Sierra
Laura Casorzo
Tim Perera
Virna Cepero
P304
P356
10.1158/0008-5472.CAN-10-0436
P407
P577
2010-09-14T00:00:00Z